IP Library › Granted Patent US 12,410,442
Granted Patent B2
US 12,410,442 · App. 17/395,711 · Granted Sep 9, 2025

Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems

Inventors: Joseph Burns (Newton, MA); Kathryn Ellis (Arlington, MA); Adam Palermo (Somerville, MA); Martin Schwander (Auburndale, MA); Jonathon Whitton (Cambridge, MA); Leah Sabin (Goldens Bridge, NY); Christos Kyratsous (Irvington, NY); Meghan Drummond Samuelson (Katonah, NY)
Assignees: Regeneron Pharmaceuticals, Inc.; Decibel Therapeutics, Inc.
C12N15/86A61K48/005C07K14/705C12N2800/40C12N2830/008C12N2840/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,442
App. No.
17/395,711
Granted
Sep 9, 2025
Kind
B2
Abstract

The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.

Claims (32)

1. A dual vector system comprising:

a first nucleic acid vector comprising a myosin 15 (Myo15) promoter operably linked to a first coding polynucleotide that encodes an N-terminal portion of an otoferlin (OTOF) protein; and

a second nucleic acid vector comprising a second coding polynucleotide that encodes a C-terminal portion of an OTOF protein and a polyadenylation (poly(A)) sequence positioned at a 3′ end of the second coding polynucleotide;

wherein the Myo15 promoter has at least 95% sequence identity to SEQ ID NO: 38, wherein neither the first nor second nucleic acid vector encodes a full-length OTOF protein, and, when introduced into a mammalian cell, the first and second nucleic acid vectors undergo homologous recombination or concatemerization to form a recombined nucleic acid that encodes a full-length OTOF protein.

2. The dual vector system of claim 1 , wherein

the first nucleic acid vector further comprises a splice donor signal sequence positioned at a 3 ‘end of the first coding polynucleotide; and

the second nucleic acid vector further comprises a splice acceptor signal sequence positioned 5’ of the second coding polynucleotide;

wherein the first coding polynucleotide and the second coding polynucleotide do not overlap.

3. The dual vector system of claim 2 , wherein

the first nucleic acid vector further comprises a first recombinogenic region positioned 3′ of the splice donor signal sequence; and

the second nucleic acid vector further comprises a second recombinogenic region positioned 5′ of the splice acceptor signal sequence positioned.

4. The dual vector system of claim 3 , wherein the first and second recombinogenic regions have the same nucleic acid sequence.

5. The dual vector system of claim 1 , wherein the first and second nucleic acid vectors are adeno-associated virus (AAV) vectors.

6. The dual vector system of claim 1 , wherein the first and second coding polynucleotides that encode the OTOF protein do not comprise introns.

7. The dual vector system of claim 1 , wherein the Myo15 promoter has the sequence of SEQ ID NO: 38.

8. The dual vector system of claim 3 , wherein each of the first and second recombinogenic regions is an AP gene fragment or an F1 phage AK gene.

9. The dual vector system of claim 1 , wherein the OTOF protein is a human OTOF protein.

10. The dual vector system of claim 5 , wherein the first and second nucleic acid vectors comprise an inverted terminal repeat (ITR) at each end of the nucleic acid sequence.

11. The dual vector system of claim 10 , wherein the ITR is an AAV2 ITR.

12. The dual vector system of claim 1 , wherein the poly(A) sequence is a bovine growth hormone (bGH) poly(A) signal sequence.

13. The dual vector system of claim 7 , wherein the OTOF protein is a human OTOF protein.

14. The dual vector system of claim 13 , wherein the first and second coding polynucleotides that encode the OTOF protein do not comprise introns.

15. The dual vector system of claim 14 , wherein

the first nucleic acid vector further comprises a splice donor signal sequence positioned at a 3 ‘end of the first coding polynucleotide; and

the second nucleic acid vector further comprises a splice acceptor signal sequence positioned 5’ of the second coding polynucleotide;

wherein the first coding polynucleotide and the second coding polynucleotide do not overlap.

16. The dual vector system of claim 15 , wherein

the first nucleic acid vector further comprises a first recombinogenic region positioned 3′ of the splice donor signal sequence; and

the second nucleic acid vector further comprises a second recombinogenic region positioned 5′ of the splice acceptor signal sequence positioned.

17. The dual vector system of claim 16 , wherein the first and second recombinogenic regions have the same nucleic acid sequence.

18. The dual vector system of claim 17 , wherein each of the first and second recombinogenic regions is an AP gene fragment or an F1 phage AK gene.

19. The dual vector system of claim 16 , wherein the first and second nucleic acid vectors are adeno-associated virus (AAV) vectors.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2023
From: SABIN, LEAH; KYRATSOUS, CHRISTOS; DRUMMOND SAMUELSON, MEGHAN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 064324/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2022
From: SCHWANDER, MARTIN
To: DECIBEL THERAPEUTICS, INC.
Reel/Frame 059169/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2022
From: PALERMO, ADAM
To: DECIBEL THERAPEUTICS, INC.
Reel/Frame 059169/0404 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2022
From: WHITTON, JONATHON
To: DECIBEL THERAPEUTICS, INC.
Reel/Frame 059169/0512 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2022
From: BURNS, JOSEPH
To: DECIBEL THERAPEUTICS, INC.
Reel/Frame 059169/0757 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2022
From: ELLIS, KATHRYN
To: DECIBEL THERAPEUTICS, INC.
Reel/Frame 059170/0215 →
Continuity (5)
Continuation PCTUS2020017257 · Feb 7, 2020
Provisional Application 62965770 · Jan 24, 2020
Provisional Application 62928279 · Oct 30, 2019
Provisional Application 62802890 · Feb 8, 2019
Related Publication 20210395781A1 · Dec 23, 2021
References Cited (175)
US 6436392B1 · Engelhardt et al. · 2002 [cited by applicant]
US 6544786B1 · Xiao et al. · 2003 [cited by applicant]
US 6808922B1 · Bebbington et al. · 2004 [cited by applicant]
US 6897045B2 · Engelhardt et al. · 2005 [cited by applicant]
US 7803622B2 · Engelhardt et al. · 2010 [cited by applicant]
US 8236557B2 · Dongsheng et al. · 2012 [cited by applicant]
US 8298818B2 · Boye et al. · 2012 [cited by applicant]
US 10214572B2 · Boye et al. · 2019 [cited by applicant]
US 11325956B2 · Boye et al. · 2022 [cited by applicant]
US 11525139B2 · Simons et al. · 2022 [cited by applicant]
US 11660353B2 · Burns et al. · 2023 [cited by applicant]
US 11781145B2 · Simons et al. · 2023 [cited by applicant]
US 11807867B2 · Simons et al. · 2023 [cited by applicant]
US 12188041B2 · Dyka et al. · 2025 [cited by applicant]
US 12233136B2 · Burns et al. · 2025 [cited by applicant]
US 20030219741A1 · Isogai et al. · 2003 [cited by applicant]
US 20040072154A1 · Morris et al. · 2004 [cited by applicant]
US 20070161031A1 · Trinklein et al. · 2007 [cited by applicant]
US 20070161110A1 · Iida et al. · 2007 [cited by applicant]
US 20080249052A1 · Duan et al. · 2008 [cited by applicant]
US 20100003218A1 · Duan et al. · 2010 [cited by applicant]
US 20100266551A1 · Richard et al. · 2010 [cited by applicant]
US 20120003190A1 · Yamoah et al. · 2012 [cited by applicant]
US 20120087862A1 · Hood et al. · 2012 [cited by applicant]
US 20130210895A1 · Boye et al. · 2013 [cited by applicant]
US 20140249208A1 · Bancel et al. · 2014 [cited by applicant]
US 20140256802A1 · Boye et al. · 2014 [cited by applicant]
US 20150065562A1 · Yazicioglu et al. · 2015 [cited by applicant]
US 20150209406A1 · Chen · 2015 [cited by applicant]
US 20160022836A1 · Banfi et al. · 2016 [cited by applicant]
US 20160076054A1 · Auricchio et al. · 2016 [cited by applicant]
US 20180015172A1 · Muzyczka et al. · 2018 [cited by applicant]
US 20180055908A1 · Petit et al. · 2018 [cited by applicant]
US 20180327779A1 · Colella et al. · 2018 [cited by applicant]
US 20190002916A1 · Kalatzis et al. · 2019 [cited by applicant]
US 20190153050A1 · Boye et al. · 2019 [cited by applicant]
US 20190185864A1 · Simons et al. · 2019 [cited by applicant]
US 20190309326A1 · Maclaren et al. · 2019 [cited by applicant]
US 20200155705A1 · Burns et al. · 2020 [cited by applicant]
US 20200157573A1 · Boye et al. · 2020 [cited by applicant]
US 20210130421A1 · Boye et al. · 2021 [cited by applicant]
US 20210236654A1 · Burns et al. · 2021 [cited by applicant]
US 20210388045A1 · Burns et al. · 2021 [cited by applicant]
US 20210395778A1 · Dyka et al. · 2021 [cited by applicant]
US 20220064671A1 · Maranga et al. · 2022 [cited by applicant]
US 20220265865A1 · Burns et al. · 2022 [cited by applicant]
US 20230149565A1 · Boye et al. · 2023 [cited by applicant]
US 20240011039A1 · Simons et al. · 2024 [cited by applicant]
US 20240131186A1 · Burns et al. · 2024 [cited by applicant]
US 20240148905A1 · Palermo et al. · 2024 [cited by applicant]
US 20240309399A1 · Hu et al. · 2024 [cited by applicant]
WO WO0125465A1 · 2001 [cited by applicant]
WO WO2001070972A2 · 2001 [cited by applicant]
WO WO2008088895A2 · 2008 [cited by applicant]
WO WO2009100438A2 · 2009 [cited by applicant]
WO WO2013075008A1 · 2013 [cited by applicant]
WO WO2013158879A1 · 2013 [cited by applicant]
WO WO2014140051A1 · 2014 [cited by applicant]
WO WO2014170480A1 · 2014 [cited by applicant]
WO WO2014193716A2 · 2014 [cited by applicant]
WO WO2016131981A1 · 2016 [cited by applicant]
WO WO2016139321A1 · 2016 [cited by applicant]
WO WO2017049252A1 · 2017 [cited by applicant]
WO WO2017100791A1 · 2017 [cited by applicant]
WO WO2017216560A1 · 2017 [cited by applicant]
WO WO2018039375A1 · 2018 [cited by applicant]
WO WO2018145111A1 · 2018 [cited by applicant]
WO WO2018162748A1 · 2018 [cited by applicant]
WO WO2018204734A1 · 2018 [cited by applicant]
WO WO2019162396A1 · 2019 [cited by applicant]
WO WO2019165292A1 · 2019 [cited by applicant]
WO WO2019183641A1 · 2019 [cited by applicant]
WO WO2020093018A1 · 2020 [cited by applicant]
WO WO2020097372A1 · 2020 [cited by applicant]
WO WO2020148458A1 · 2020 [cited by applicant]
WO WO2021087296A1 · 2021 [cited by applicant]
WO WO2024173835A2 · 2024 [cited by applicant]
Liang et al., “Characterization of the Human and Mouse Unconventional Myosin XV Genes Responsible for Hereditary Deafness DFNB3 and Shaker 2,” Genomics. 61(3):243-258 (1999). [cited by applicant]
Yuhe, Liu, “Preparation of adeno-associated virus vector and its application in cochlea transgenic research,” Chinese Journal of Otology. 4(4):343-347 (2006) (6 pages). [cited by applicant]
Hirsch et al., “Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors,” available in PMC Aug. 3, 2016, published in final edited form as: Methods Mol Biol. 13382:21-39 (2016) (20 pages). [cited by applicant]
Majewski and Ott, “GT Repeats Are Associated with Recombination on Human Chromosome 22,” Genome Res. 10(8): 1108-1144 (Aug. 2000) (7 pages). [cited by applicant]
Lostal et al., “Full-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors, ” Human Gene Ther. 25(6): 552-562 (Jun. 2014) (11 pages). [cited by applicant]
Gao et al., “The Dystrophin Complex: structure, function and implications for therapy,” available in PMC Jul. 1, 2016, published in final edited form as: Compr Physiol. 5(3): 1223-1239 (Jul. 2015) (33 pages). [cited by applicant]
Dyka et al., “Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A,” Human Gene Ther Methods. 25(2): 166-77 (Apr. 2014) (12 pages). [cited by applicant]
Pryadkina et al., “A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb Dysferlin coding sequence,” Mol Ther Methods Clin Dev. 2: 15009 (Mar. 2015) (12 pages). [cited by applicant]
Geleoc et al., “Sound strategies for hearing restoration,” available in PMC Aug. 29, 2014, published in final edited form as: Science. 344(6184):1241062 (May 2014) (20 pages). [cited by applicant]
Al-Moyed et al., “A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice,” EMBO Mol Med. 11(1):e9396 (2019) (13 pages). [cited by applicant]
GenBank Accession No. JN953192.1, “Mus musculus targeted KO-first, conditional ready, lacZ-tagged mutant allele Myo15:tm1a(EUCOMM)Wtsi; transgenic,” retrieved from <https://www.ncbi.nlm.nih.gov/nuccore/JN953192>, dated … [cited by applicant]
Caberlotto et al., “Usher type 1G protein sans is a critical component of the tip-link complex, a structure controlling actin polymerization in stereocilia,” Proc Natl Acad Sci U S A. 108(14):5825-30 (2011) (14 pages). [cited by applicant]
Schlabach et al., “Synthetic design of strong promoters,” Proc Natl Acad Sci U S A. 107(6):2538-43 (2010). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/029366, mailed Sep. 10, 2019 (17 pages). [cited by applicant]
Boëda et al., “A specific promoter of the sensory cells of the inner ear defined by transgenesis,” Hum Mol Genet. 10(15):1581-1589 (2001). [cited by applicant]
Belyantseva et al., “Myosin XVa localizes to the tips of inner ear sensory cell stereocilia and is essential for staircase formation of the hair bundle,” Proc Natl Acad Sci U S A. 100(24):13958-63 (2003). [cited by applicant]
GenBank Accession No. JN957158.1, “Mus musculus targeted non-conditional, lacZ-tagged mutant allele Myo15:tm1e(EUCOMM) Wtsi; transgenic,” retrieved from <https://www.ncbi.nlm.nih.gov/nucleotide/JN957158.1>, dated Nov. 5… [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2020/017292, mailed Jun. 26, 2020 (18 pages). [cited by applicant]
Akil et al., “Dual AAV gene therapy restores hearing in a mouse model for human genetic Deafness,” International Symposium on Inner Ear Therapies (ISIET), Marrakech, Morocco. 21 (2017) (Abstract only). [cited by applicant]
Akil et al., “Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model,” Proc Natl Acad Sci U S A. 116(10):4496-4501 (2019). [cited by applicant]
Al-Moyed et al., “A dual AAV viral vector approach partially restores exocytosis and rescues hearing in deaf otoferlin knock-out mice,” ARO Abstracts. 41:76 (2018) (Abstract only). [cited by applicant]
Alemi, “Progress Report: AOS Research Grant: Restoration of Hearing in the Otoferlin Knockout Mouse using Viral Gene Therapy,” 145th Annual Meeting of the American Otological Society, Inc, Apr. 21-22, San Diego, Califor… [cited by applicant]
Choi et al., “Identities and frequencies of mutations of the otoferlin gene (OTOF) causing DFNB9 deafness in Pakistan,” available in PMC Oct. 1, 2012, published in final edited form as: Clin Genet. 75(3):237-243 (2009) … [cited by applicant]
Duan et al., “Expanding AAV Packaging Capacity with Trans-splicing or Overlapping Vectors: A Quantitative Comparison,” Mol Ther. 4(4):383-91 (2001). [cited by applicant]
McClements et al., “Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes,” Yale J Biol Med. 90(4):611-623 (2017). [cited by applicant]
Trapani et al., “Effective delivery of large genes to the retina by dual AAV vectors,” EMBO Mol Med. 6(2):194-211 (2014). [cited by applicant]
Trapani et al., “Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease,” Hum Mol Genet. 24(23):6811-25 (2015). [cited by applicant]
Yasunaga et al., “ [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/017257, mailed Apr. 29, 2020 (22 pages). [cited by applicant]
Xu et al., “Trans-Splicing Adeno-Associated Viral Vector-Mediated Gene Therapy Is Limited by the Accumulation of Spliced mRNA but Not by Dual Vector Coinfection Efficiency,” available in PMC Jun. 19, 2008, published in … [cited by applicant]
Ghosh et al., “A Hybrid Vector System Expands Adeno-associated Viral Vector Packaging Capacity in a Transgene-independent Manner,” The American Society of Gene Therapy. 16(1):124-130 (2008). [cited by applicant]
Ghosh et al., “Efficient Transgene Reconstitution with Hybrid Dual AAV Vectors Carrying the Minimized Bridging Sequences,” Hum Gene Ther. 22(1):77-83 (2011). [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2020/058265, mailed Feb. 8, 2021 (15 pages). [cited by applicant]
Michalski et al., “Genetics of auditory mechano-electrical transduction,” Pflugers Arch. 467(1):49-72 (2015). [cited by applicant]
Skarnes et al., “A conditional knockout resource for the genome-wide study of mouse gene function,” available in PMC Feb. 14, 2013, published in final edited form as: Nature. 474(7351):337-342 (2011) (18 pages). [cited by applicant]
Boye et al., “Transduction and Tropism of an Abbreviated Form of CMV-Chicken B-Actin Promoter (CBA) With AAV in Mouse Retina,” ARVO Annual Meeting Abstract May 2006, published in: Investigative Ophthalmology & Visual Sc… [cited by applicant]
Lovell, “Mouse DNA sequence from clone RP23-135F6 on chromosome 11,” European Nucleotide Archive, EMBL-EBI. (2012) (15 pages). [cited by applicant]
Higashimoto et al., “The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors,” Gene Ther. 14(17):1298-304 (2007). [cited by applicant]
Wang, Aihui, Dissertation: “Molecular Cloning of an Unconventional Myosin MYO15 and the Identification of Mutations of MYO15 Responsible for Human Nonsyndromic Deafness DFNB3,” Doctor of Philosophy, Graduate Program in … [cited by applicant]
Corns et al., “Mechanotransduction is required for establishing and maintaining mature inner hair cells and regulating efferent innervation,” Nat Commun. 9(1):4015 (Oct. 2018) (15 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2022/017058, dated Jun. 14, 2022 (14 pages). [cited by applicant]
Yoshimura et al., “Enhanced viral-mediated cochlear gene delivery in adult mice by combining canal fenestration with round window membrane inoculation,” Scientific Reports. 8:2980 (with supplemental material) (Feb. 2018… [cited by applicant]
Pangrsic et al., “Otoferlin: a multi-C [cited by applicant]
Holt et al., “Split otoferlin reunited,” EMBO Molecular Medicine. 11:(1)e9995 (Jan. 2019) (3 pages). [cited by applicant]
Suzuki et al., “Cochlear gene therapy with ancestral AAV in adult mice: complete transduction of inner hair cells without cochlear dysfunction,” Scientific Reports. 7(1):45524 (Apr. 2017) (11 pages). [cited by applicant]
Tertrais et al., “Viral Transfer of Mini-Otoferlins Partially Restores the Fast Component of Exocytosis and Uncovers Ultrafast Endocytosis in Auditory Hair Cells of Otoferlin Knock-Out Mice,” J. Neurosci. 39(18):3394-34… [cited by applicant]
Petrs-Silva et al., “Novel Properties of Tyrosine-mutant AAV2 Vectors in the Mouse Retina,” Molecular Therapy. 19(2):293-301 (Feb. 2011) (9 pages). [cited by applicant]
American Academy of Audiology, “Children's Hospital of Philadelphia Performs First Gene Therapy Procedure to Treat Genetic Hearing Loss in United States,” <https://www.audiology.org/childrens-hospital-of-philadelphia-pe… [cited by applicant]
Yoshimura et al., “Targeted Allele Suppression Prevents Progressive Hearing Loss in the Mature Murine Model of Human [cited by applicant]
Akil et al., “Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane,” Journal of Visualized Experiments. 97(1):e52187 (Mar. 2015) (7 pages). [cited by applicant]
Liu et al., “Specific and Efficient Transduction of [cited by applicant]
“Basics of sound, the Ear, and Hearing,” [cited by applicant]
Akil et al., “AAV-Mediated Gene Delivery to the Inner Ear,” [cited by applicant]
Langouet-Astrie et al., “Characterization of intravitreally delivered capsid mutant AAV2-Cre vector to induce tissue-specific mutations in murine retinal ganglion cells,” Experimental Eye Research. 151(1):61-67 (Jul. 20… [cited by applicant]
Li et al., “A novel bispecific molecule delivered by recombinant AAV2 suppresses ocular inflammation and choroidal neovascularization,” J. Cell. Mol. Med. 21(8):1555-1571 (Aug. 2017) (17 pages). [cited by applicant]
Lopes-Pacheco et al., “Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells,” Experimental Cell Research. 372:99-107 (Sep. 2018) (9 pages). [cited by applicant]
Petrs-Silva et al., “High-efficiency Transduction of the Mouse Retina by Tyrosine-mutant AAV Serotype Vectors,” Molecular Therapy. 17(3):463-471 (Mar. 2009) (9 pages). [cited by applicant]
Kilpatrick et al., “Adeno-associated virus-mediated gene delivery into the scala media of the normal and deafened adult mouse ear,” Gene Therapy. 18(6):569-578 (Jan. 2011) (10 pages). [cited by applicant]
Tao et al., “Delivery of Adeno-Associated Virus Vectors in Adult Mammalian Inner-Ear Cell Subtypes Without Auditory Dysfunction,” Human Gene Therapy. 29(4):492-506 (Nov. 2017) (15 pages). [cited by applicant]
Zhang et al., “Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and Major Remaining Hurdles for Translational Success,” Front. Mol. Neurosci. 11(221):1-15 (Jun. 2018) (15 pages). [cited by applicant]
Roux et al., “Otoferlin, Defective in a Human Deafness Form, Is Essential for Exocytosis at the Auditory Ribbon Synapse,” Cell. 127(2):277-289 (Oct. 2006) (13 pages). [cited by applicant]
“Genetic Hearing Loss With No. Associated Abnormalities,” [cited by applicant]
Ahmed et al., “Emerging Gene Therapies for Genetic Hearing Loss,” JARO. 18(5):649-670 (Aug. 2017) (22 pages). [cited by applicant]
Zhang et al., “Temperature sensitive auditory neuropathy,” Hearing Research. 335(1):53-63 (Jan. 2016) (11 pages). [cited by applicant]
Hamosh et al. “OTOFERLIN; OTOF,” OMIM. (Apr. 2015) (8 pages) retrieved via The Wayback Machine on Jul. 29, 2015, URL: <https://web.archive.org/web/20150729163826/http://omim.org/entry/603681>. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2024/016218, mailed Jul. 12, 2024 (19 pages). [cited by applicant]
Kim et al., “Direct isolation and identification of promoters in the human genome,” Genome Res. 15(6):830-9 (Jun. 2005) (11 pages). [cited by applicant]
U.S. Appl. No. 17/290,082, Dyka et al. [cited by applicant]
U.S. Appl. No. 16/952,016, Boye et al. [cited by applicant]
U.S. Appl. No. 17/916,308, Boye et al. [cited by applicant]
GenPept Accession NP_001274418.1, dated Apr. 23, 2017, (4 pages) retrieved from https://www.ncbi.nlm.nih.gov/protein/566559996?sat=46&satkey=73202094. [cited by applicant]
McClements et al., “A fragmented adeno-associated viral dual vector strategy for treatment of diseases caused by mutations in large genes leads to expression of hybrid transcripts,” J Genet Syndr Gene Ther. 7(5):311 (No… [cited by applicant]
Avraham, “What's hot about otoferlin,” Embo J. 35(23):2502-4 (Dec. 1, 2016). [cited by applicant]
NCBI Reference Sequence: NM_001632.5, “Homo sapiens alkaline phosphatase, placental (ALPP), mRNA” (Apr. 4, 2024) (5 pages). [cited by applicant]
NCBI Reference Sequence: NP_000251.3, “unconventional myosin-Vlla isoform 1 [Homo sapiens]” (Dec. 11, 2024) (5 pages). [cited by applicant]
GenBank: U39226.1, “Human myosin Viia (USH1B) mRNA, complete cds” (Jul. 11, 1996) (4 pages). [cited by applicant]
Akil et al., “Restoration of Hearing in the VGLUT3 Knockout Mouse Using Virally Mediated Gene Therapy,” Neuron. 75:283-293 (2012). [cited by applicant]
Al-Hussaini et al., “Mature retinal pigment epithelium cells are retained in the cell cycle and proliferate in vivo,” Mol Vis. 14:1784-91 (2008). [cited by applicant]
Allocca et al., “Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice,” J Clin Invest. 118(5):1955-64 (May 2008) (11 pages). [cited by applicant]
Chen et al., “Molecular cloning and domain structure of human myosin-Vlla, the gene product defective in Usher syndrome 1B,” Genomics 36(3):440-8 (Sep. 15, 1996). [cited by applicant]
Daya et al., “Gene therapy using adeno-associated virus vectors,” Clin Microbiol Rev. 21(4):583-93 (Oct. 2008). [cited by applicant]
Dong et al., “Characterization of genome integrity for oversized recombinant AAV vector,” Mol Ther. 18(1):87-92 (Jan. 2010). [cited by applicant]
Duan et al., “Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue,” J Virol. 72(11):8568-77 (Nov. 1998). [cited by applicant]
Hashimoto et al., “Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B,” Gene Ther. 14(7):584-94 (Apr. 2007) (21 pages). [cited by applicant]
Jacobson et al., “Usher syndromes due to MYO7A, PCDH15, USH2A or GPR98 mutations share retinal disease mechanism,” Hum Mol Genet. 17(15):2405-15 (Aug. 1, 2008). [cited by applicant]
Lai et al., “Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb,” Mol Ther. 18(1): 75-9 (Jan. 2010). [cited by applicant]
Li et al., “High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy,” Hum Gene Ther. 21(11):1527-43 (Nov. 2010) (18 pages). [cited by applicant]
Lopes et al., “Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus,” Gene Ther. 20(8):824-33 (Aug. 2013) (21 pages). [cited by applicant]
Weil et al., “Human myosin VIIA responsible for the Usher 1B syndrome: a predicted membrane-associated motor protein expressed in developing sensory epithelia,” Proc Natl Acad Sci USA. 93(8):3232-7 (Apr. 16, 1996). [cited by applicant]
Wu et al., “Effect of genome size on AAV vector packaging,” Mol Ther. 18(1):80-6 (Jan. 2010). [cited by applicant]
Yan et al., “Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes,” J Virol. 79(1):364-79 (Jan. 2005). [cited by applicant]
Freni et al., “Cochlear Implant Surgery: Endomeatal Approach versus Posterior Tympanotomy,” Int. J. Environ. Res. Public Health 17:4187 (Jun. 2020) (9 pages). [cited by applicant]
“Types of CFTR Mutations,” Cystic Fibrosis Foundation. < https://www.cff.org/research-clinical-trials/types-cftr-mutations#:-: text=>, accessed Mar. 1, 2025 (9 pages). [cited by applicant]
Barnes et al., “Remarkable Rigidity of the Single a-Helical Domain of Myosin-VI As Revealed by NMR Spectroscopy,” J Am Chem Soc. 141(22):9004-9017 (Jun. 2019). [cited by applicant]
Laine et al., “Cell cycle regulation in the inner ear sensory epithelia: role of cyclin D1 and cyclin-dependent kinase inhibitors,” Dev Biol. 337(1):134-46 (Jan. 2010). [cited by applicant]
Orthwein et al., “A mechanism for the suppression of homologous recombination in G1 cells,” Nature. 528(7582):422-6 (Dec. 2015); retraction in: Nature. 638(8051):844 (Feb. 2025) (35 pages). [cited by applicant]
Regalado et al., “Some deaf children in China can hear after gene therapy treatment,” MIT Technology Review. <https://www.technologyreview.com/2023/10/27/1082551/gene-treatment-deaf-children-hearing-china/>, published O… [cited by applicant]
Zhang et al., “Single amino acid change alters specificity of the multi-allelic wheat stem rust resistance locus SR9,” Nat Commun. 14(1):7354 (Nov. 2023) (12 pages). [cited by applicant]